Delving into the Latest Updates on GD-N1801 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

Target-

Action-

Mechanism-

Therapeutic Areas

Other Diseases

Active Indication

Wounds and Injuries

Inactive Indication-

Originator Organization

Sichuan Gooddoctor Panxi Pharmaceutical Co. Ltd.

Active Organization

Sichuan Gooddoctor Panxi Pharmaceutical Co. Ltd.Luoxin Aurovitas Pharma(Chengdu) Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Primary objective: To evaluate the safety and tolerability of GD-N1801 topical solution after single and multiple administrations in healthy adult subjects. Secondary objective: To evaluate the pharmacokinetic characteristics of GD-N1801 topical solution after single and multiple administrations in healthy adult subjects.

Start Date-

Sponsor / Collaborator

Luoxin Aurovitas Pharma(Chengdu) Co., Ltd.

[+1]

100 Clinical Results associated with GD-N1801

Login to view more data

100 Translational Medicine associated with GD-N1801

Login to view more data

100 Patents (Medical) associated with GD-N1801

Login to view more data

100 Deals associated with GD-N1801

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Wounds and Injuries	Phase 1	China	Sichuan Gooddoctor Panxi Pharmaceutical Co. Ltd.	11 Mar 2025
Wounds and Injuries	Phase 1	China	Luoxin Aurovitas Pharma(Chengdu) Co., Ltd.	11 Mar 2025